Some sexually transmitted infections can change vaginal discharge, but many cause no symptoms at all. Discharge colour, smell or texture cannot identify an STI or rule one out. The useful next step is risk- and anatomy-based testing, followed by infection-specific treatment, follow-up and partner care.
📚 Articles in This Cluster
Written by the Dr. Dina Rezk Clinic editorial team, based on CDC, WHO, IUSTI and other sources listed below. This article is educational and cannot diagnose an STI or pelvic inflammatory disease without medical assessment.
Key takeaways
- Normal discharge does not rule out an STI. Chlamydia and gonorrhoea are often asymptomatic, and trichomoniasis ranges from no symptoms to genital irritation and discharge (CDC chlamydia guidance; CDC gonorrhoea guidance; CDC trichomoniasis guidance).
- Discharge cannot name the organism. Trichomoniasis and cervicitis caused by chlamydia or gonorrhoea can change discharge, but colour and odour overlap with BV, yeast, normal variation and noninfectious irritation.
- There is no universal “vaginal swab for everything.” The right test and sample depend on anatomy, sexual exposure sites, symptoms, pregnancy and the infection being considered. NAAT is preferred for chlamydia and gonorrhoea; sensitive molecular tests are used for trichomoniasis (CDC cervicitis guidance; CDC trichomoniasis guidance).
- Treatment is infection-specific. Chlamydia, gonorrhoea and trichomoniasis require different regimens, with additional decisions for pregnancy, allergy, infection site and antimicrobial resistance (WHO 2024 STI recommendations; WHO 2024 gonorrhoea and chlamydia recommendations).
- Partner care is not one rule. Notification, evaluation, treatment, abstinence, test of cure and retesting vary by infection and situation. Follow the plan given for the confirmed diagnosis.
- Pelvic pain changes the urgency. Lower abdominal or pelvic pain, fever, vomiting, pain with examination or severe illness can indicate pelvic inflammatory disease (PID), which may be subtle and needs prompt care (CDC PID guidance).
Table of contents
- Which STIs can affect vaginal discharge?
- Symptoms and asymptomatic infection
- A clinical decision framework
- What happens during an assessment?
- How STI testing works
- Testing windows, test of cure and retesting
- Treatment principles
- Partner notification and care
- PID escalation
- Pregnancy and adolescent safeguarding
- Red flags
- Frequently asked questions
- The bottom line
- References
Which STIs can affect vaginal discharge?
Trichomoniasis can cause vaginitis and discharge. Chlamydia and gonorrhoea can cause cervicitis, meaning inflammation of the cervix, which may produce abnormal discharge or bleeding. Yet all three infections may be present without noticeable symptoms, so testing should follow exposure risk and clinical findings rather than appearance alone (CDC trichomoniasis guidance; CDC cervicitis guidance).
The vagina is the internal canal, while the cervix is the opening of the uterus at the top of the vagina. Vaginitis mainly affects the vaginal environment. Cervicitis affects the cervix. A person may experience both, or neither may cause obvious symptoms. This anatomy helps explain why a discharge sample alone is not always the complete assessment.
Trichomoniasis
Trichomoniasis is caused by the protozoan Trichomonas vaginalis. Most infected people have minimal or no symptoms, according to CDC and WHO guidance. When symptoms occur, they can include genital itching, burning, soreness, discomfort with urination and a change in discharge. The discharge can vary; no colour, texture or smell proves trichomoniasis (CDC; WHO).
Chlamydia
Chlamydia trachomatis infection is often asymptomatic. When it causes cervicitis, possible features include discharge between the vagina and cervix, bleeding between periods or after sex, and urinary symptoms. These signs overlap with other infections and noninfectious conditions. Untreated infection can be associated with upper genital tract complications, but a positive diagnosis is not a verdict about future fertility (CDC).
Gonorrhoea
Neisseria gonorrhoeae can infect the cervix and other exposed sites. Cervical infection may cause discharge, urinary symptoms or bleeding, but many women have no symptoms or mild nonspecific symptoms. Gonorrhoea treatment must account for antimicrobial resistance and the site of infection, which is why leftover antibiotics or an online colour diagnosis is unsafe (CDC; WHO recommendations).
Other infections in the differential
Herpes may cause painful blisters or ulcers rather than a characteristic discharge, while HIV and syphilis frequently require blood testing based on exposure rather than a discharge pattern. Mycoplasma genitalium may be considered in selected persistent or recurrent cervicitis pathways, but it is not a reason for a universal panel. BV and vaginal yeast infection are not classified as the same type of STI, although symptoms can overlap. See bacterial vaginosis and vaginal yeast infection for those separate pathways.
Having an STI does not mean someone is “dirty,” careless or unfaithful. An infection may have been present silently, and a test result cannot establish when it was acquired without other evidence. Care should focus on health, treatment and prevention of onward transmission.
If symptoms, exposure or screening needs concern you, consider a general gynecological assessment. Choose a service that can confirm which testing and partner-care options it provides.
Symptoms and asymptomatic infection
Possible features of trichomoniasis or cervicitis include:
- a new change in vaginal discharge;
- genital itching, irritation or soreness;
- burning with urination;
- bleeding between periods or after sex;
- discomfort during sex;
- lower abdominal or pelvic pain;
- no symptoms at all.
The last point matters most. CDC guidance describes asymptomatic infection as common for chlamydia, gonorrhoea and trichomoniasis (CDC chlamydia guidance; CDC gonorrhoea guidance; CDC trichomoniasis guidance). Waiting for coloured discharge can therefore miss infection. Equally, discharge after a new sexual contact does not automatically mean an STI.
| Pattern | What it may prompt a clinician to consider | What it cannot prove |
|---|---|---|
| New discharge without pain | Vaginitis, cervicitis, normal cycle change, BV, yeast or irritation | Whether an STI is present or absent |
| Discharge plus bleeding after sex | Cervicitis, cervical tissue change, trauma or another cervical cause | Chlamydia or gonorrhoea from appearance alone |
| Discharge plus itching or soreness | Trichomoniasis, yeast, irritation, dermatosis or mixed causes | Which organism is responsible |
| Discharge plus pelvic pain or fever | PID or another pelvic/abdominal condition requiring prompt assessment | The cause or severity without examination |
| No discharge or other symptoms | Asymptomatic STI remains possible after exposure | That no testing is needed |
A vaginal pH test cannot diagnose an STI. The FDA explains that home pH tests may help indicate whether symptoms need evaluation, but they do not identify the cause and cannot detect infections such as chlamydia or gonorrhoea (FDA). A normal pH also cannot clear a partner or replace infection-specific testing.
Discharge can change during the menstrual cycle, pregnancy, after semen exposure and with products or irritation. The vaginal discharge overview explains normal variation, and the colour guide shows why colour is a clue rather than a test.
A clinical decision framework
This framework helps you choose a level of care without diagnosing from symptoms.
Step 1: Identify emergency or PID features
Severe or worsening pelvic or abdominal pain, collapse or fainting, heavy bleeding, confusion, breathing difficulty or severe systemic illness needs emergency assessment. In Saudi Arabia, call ambulance 997 or go to the nearest emergency department (Saudi national portal).
Pelvic or lower-abdominal pain with fever, vomiting, abnormal bleeding, pain with sex or feeling unwell warrants prompt assessment for PID or another urgent cause. Do not wait for a discharge colour to change.
Step 2: Consider exposure and screening, not just symptoms
Testing may be appropriate after condomless vaginal, anal or oral sex; a new partner; a partner’s positive result; sexual assault; a condom failure; or another exposure relevant to the infection. Screening recommendations also depend on age, pregnancy and risk factors. A clinician or local public-health service should apply the current local pathway.
Step 3: Map anatomy and sites of exposure
A vaginal or cervical specimen may be suitable for genital chlamydia or gonorrhoea testing. Urine may be an alternative in some settings. Throat or rectal exposure can require site-specific samples because a genital test does not automatically detect infection elsewhere (CDC chlamydia guidance; CDC gonorrhoea guidance). Tell the clinician which body sites were exposed so the test plan is complete.
Step 4: Check timing
No single window period applies to every STI or test. Testing immediately after an exposure can be too early for reliable detection, while symptoms may still need assessment now. Ask the testing service what assay it uses, when that test becomes informative and whether a repeat is needed. If preventive treatment after a high-risk exposure might be time-sensitive, seek urgent professional advice rather than waiting for a window to close.
Step 5: Follow the exact result plan
A positive result should trigger organism-specific treatment, partner care and advice on sexual contact. A negative result may need interpretation if testing was early, the wrong site was sampled, antibiotics were already taken or another condition is causing symptoms. Test of cure and routine retesting are different, and neither is universal.
What happens during an assessment?
A good assessment should be factual, respectful and under your control. It may begin with questions about symptoms, menstrual and pregnancy context, medicines, allergies, previous results and treatment. Sexual-health questions usually cover types and timing of contact, barrier use, exposed anatomical sites and whether a partner has symptoms or a diagnosis. These questions determine testing; they should not be used to judge identity, relationship status or choices.
You can say what language and terms you prefer. You can also ask why a question or examination is needed, request a pause, or decline a part of the assessment. Trauma history does not have to be disclosed in detail to request a slower approach. A simple statement such as “I need you to explain each step and ask before touching” is enough.
Depending on symptoms, an external examination may check for irritation, sores or skin changes. A speculum examination may be offered to see the vaginal walls and cervix or collect a sample. Discomfort varies. If an examination is not tolerable or not clinically necessary, ask whether a self-collected vaginal sample or another validated specimen is suitable for the specific test. Availability and validation differ by service and assay.
If pelvic pain raises concern for PID, abdominal and pelvic examination may help identify tenderness. CDC advises a low threshold for PID diagnosis because symptoms can be subtle and delay matters (CDC PID guidance). Ultrasound or other tests may be used to investigate complications or alternative diagnoses, but normal imaging does not automatically rule out PID.
Confidentiality and consent rules depend on age, decision-making capacity, safeguarding duties and local law. A service should explain its policy and any limits rather than promising absolute secrecy. If you are worried about coercion, assault or someone monitoring your communications, tell a qualified professional when it is safe to do so. Medical care can proceed at a pace that prioritizes immediate safety and consent.
How STI testing works
Chlamydia and gonorrhoea
Nucleic acid amplification tests, usually called NAATs, are preferred because they are sensitive and can be used with validated vaginal, cervical, urine, rectal or throat specimens depending on the infection site and assay (CDC cervicitis guidance; CDC gonorrhoea guidance). For genital screening in women, a vaginal swab is an optimal specimen in CDC guidance, and self-collected vaginal swabs can perform comparably to clinician-collected specimens when the approved method is followed (CDC chlamydia guidance).
Culture still has a role in gonorrhoea, especially when treatment failure or antimicrobial susceptibility is a concern. A NAAT detects genetic material but generally does not provide the same susceptibility information. This resistance issue is one reason treatment should follow current guidance rather than an old prescription.
Trichomoniasis
Wet-mount microscopy can show motile trichomonads, but sensitivity is limited and falls quickly after collection. More sensitive molecular tests, including NAATs, are preferred where available and validated (CDC trichomoniasis guidance). A negative low-sensitivity test may need follow-up with a molecular test when clinical suspicion remains.
Blood tests and other sites
A discharge sample does not test for every STI. Depending on the diagnosis and exposure, clinicians may recommend blood tests for HIV and syphilis and samples from the throat or rectum. CDC advises people diagnosed with chlamydia, gonorrhoea or trichomoniasis to be tested for other STIs, including HIV, with the exact panel guided by context (CDC chlamydia guidance; CDC gonorrhoea guidance; CDC trichomoniasis guidance).
What a result does and does not mean
A positive result identifies an infection at a sampled site. It usually cannot reveal exactly when transmission occurred or who had it first. A negative result means the test did not detect the organism in that specimen at that time. It may not cover other organisms, body sites or exposures, and an early test may need repeating.
| Clinical question | Useful approach | Common mistake to avoid |
|---|---|---|
| Is chlamydia or gonorrhoea present genitally? | Validated NAAT from an appropriate vaginal, cervical or urine specimen | Assuming a general swab included NAAT |
| Was the throat or rectum exposed? | Site-specific NAAT where recommended and validated | Assuming a genital negative result covers other sites |
| Could this be trichomoniasis? | Sensitive molecular test where available; interpret microscopy limits | Ruling it out from discharge appearance or one insensitive test |
| Is resistance a concern in gonorrhoea? | Culture and susceptibility pathway when treatment failure is suspected | Repeating empirical antibiotics without evaluation |
| Should HIV or syphilis be tested? | Exposure- and diagnosis-based blood testing | Assuming vaginal discharge would reveal either infection |
Testing windows, test of cure and retesting
Three timing concepts are often confused.
A testing window is the time after exposure before a test can reliably detect infection. It depends on the organism, specimen, assay and local protocol. The fetched guidance does not support one universal “test after X days” instruction for every STI, so confirm timing with the testing service. Symptoms or time-sensitive exposure management still deserve immediate advice even if repeat testing may later be needed.
A test of cure checks whether treatment cleared the diagnosed infection. It is not routine for every infection or every patient. CDC guidance recommends a chlamydia test of cure at about four weeks after treatment during pregnancy, but not routinely for nonpregnant people unless adherence is uncertain, symptoms persist or reinfection is suspected (CDC chlamydia guidance). For gonorrhoea, test of cure is generally unnecessary after recommended treatment of uncomplicated urogenital or rectal infection, while pharyngeal gonorrhoea should be checked 7 to 14 days after treatment (CDC gonorrhoea guidance).
Retesting looks mainly for reinfection after treatment. CDC advises retesting women treated for chlamydia, gonorrhoea or trichomoniasis about three months after treatment, regardless of whether they believe partners were treated; if that is not possible, retest when the person next seeks care within 12 months (CDC chlamydia guidance; CDC gonorrhoea guidance; CDC trichomoniasis guidance). These are infection-specific CDC recommendations, not a substitute for a local clinician’s plan.
For trichomoniasis, NAAT should not be performed before three weeks after treatment when evaluating persistent or recurrent infection because residual nucleic acid may be detected (CDC trichomoniasis guidance). Timing differs across infections. Write down the planned date and purpose of each repeat test.
Treatment principles
Treatment aims to cure the infection when possible, relieve symptoms, prevent complications and reduce transmission. The exact prescription should follow a confirmed or clinically justified diagnosis and current local guidance.
| Infection or syndrome | Treatment principle | Factors that change management |
|---|---|---|
| Chlamydia | Use a recommended anti-chlamydial antibiotic regimen | Pregnancy, adherence, rectal infection, allergy and possible coinfection |
| Gonorrhoea | Use current resistance-aware recommended therapy | Body weight, infection site, allergy, susceptibility, treatment failure and chlamydia status |
| Trichomoniasis | Use an effective nitroimidazole regimen selected for the patient | Sex, pregnancy, HIV status, adherence, reinfection and persistent infection |
| Cervicitis before results | Decide whether presumptive treatment is justified or testing-led follow-up is safe | Risk, ability to follow up, local prevalence and signs of upper-tract infection |
| PID | Start broad treatment promptly when clinical criteria support PID | Pregnancy, severe illness, abscess, inability to tolerate oral treatment or uncertain diagnosis may require hospital care |
CDC and WHO recommendations differ in some details because they consider evidence, resistance patterns, feasibility and population context at different times. WHO issued updated recommendations in 2024 for common curable STIs and for chlamydia and gonorrhoea (WHO STI recommendations; WHO gonorrhoea and chlamydia recommendations). A prescriber should use the current adopted guideline and local resistance information.
Do not use leftover antibiotics, share treatment or stop early because discharge improved. Symptoms can improve before infection is cleared, and the wrong antibiotic can fail while contributing to resistance. Tell the prescriber about pregnancy possibility, breastfeeding, allergies, liver or kidney problems, other medicines and any doses already taken.
Cervicitis is a clinical syndrome, not a single organism. CDC recommends testing for chlamydia and gonorrhoea, evaluating for BV and trichomoniasis, and considering other causes in selected persistent cases (CDC cervicitis guidance). Presumptive treatment decisions depend on risk and follow-up. A negative chlamydia and gonorrhoea result does not justify endless antibiotics when symptoms persist.
After treatment, follow the infection-specific advice about sexual contact. This usually means avoiding sex until the patient and relevant partners have completed treatment and any required waiting period has passed, but the exact rule varies by regimen. Follow the instructions tied to your diagnosis rather than a blanket internet rule.
A general gynecological assessment may be appropriate for persistent discharge, bleeding, pain or uncertain findings. Seek care through a service that confirms it can arrange the necessary testing and treatment.
Partner notification and care
Partner care protects both people and reduces reinfection, but it must be matched to the organism. It should never be used to assign blame.
Chlamydia
CDC advises evaluation, testing and presumptive treatment for sex partners who had sexual contact during the 60 days before symptom onset or diagnosis. If the most recent contact was earlier, the most recent partner should still be evaluated and treated. Local law and practice determine whether expedited partner therapy is available or appropriate (CDC chlamydia guidance).
Gonorrhoea
For gonorrhoea, CDC also uses the preceding 60 days for recent partner evaluation, testing and presumptive treatment, with the most recent partner included if contact was earlier. Treatment selection must account for possible chlamydia and current gonorrhoea recommendations. Expedited partner therapy is jurisdiction- and situation-dependent, not a universal instruction (CDC gonorrhoea guidance).
Trichomoniasis
CDC says concurrent treatment of all sex partners is vital for preventing reinfection in trichomoniasis. Current partners should receive presumptive therapy and avoid sex until everyone has been treated and symptoms have resolved. The role of expedited partner therapy depends on local law and pathway (CDC trichomoniasis guidance).
How to communicate without blame
A neutral message can be enough: “A test found an infection that can be passed through sex. It can be present without symptoms, so you need assessment and treatment advice.” You do not need to speculate about timing or origin. If direct contact feels unsafe, ask the treating service about available partner-notification options.
Do not apply STI partner rules to yeast or BV. Routine partner treatment is not recommended for uncomplicated VVC, while BV partner guidance is evolving and belongs to the bacterial vaginosis guide. Different diagnoses require different advice.
If notifying someone could expose you to violence, coercion, homelessness or surveillance, prioritize safety. Tell a qualified service about the risk before contacting the partner. Do not use a confrontation as a medical requirement.
PID escalation
Pelvic inflammatory disease is infection and inflammation of the upper genital tract. It can involve the uterus, fallopian tubes and nearby structures. Chlamydia and gonorrhoea are important causes, but not every PID case has either organism identified (CDC PID guidance).
PID can be subtle. Mild pelvic pain, abnormal bleeding, pain with sex or cervical discharge may be the only clues. CDC recommends a low threshold for presumptive treatment in sexually active young women and others at risk when pelvic or lower-abdominal pain has no better explanation and examination finds cervical motion, uterine or adnexal tenderness (CDC PID guidance). This is a clinician’s threshold, not a self-examination instruction.
Prompt assessment matters because treatment cannot reverse damage that has already occurred. At the same time, fertility statistics should not be used to frighten someone. A PID diagnosis does not mean infertility is inevitable. The practical priorities are timely treatment, completing the regimen, checking response and managing relevant partners.
Hospital assessment may be needed when pregnancy is possible, severe illness or vomiting prevents oral treatment, a tubo-ovarian abscess is suspected, another surgical emergency cannot be excluded, or outpatient treatment is not working (CDC PID guidance). NHS guidance also advises urgent assessment for severe or worsening pain, heavy bleeding, dizziness or fainting, high temperature, vomiting or feeling very unwell (NHS).
Do not press deeply on your abdomen, insert fingers to check tenderness or attempt a cervical self-examination. If pelvic pain persists after urgent infection issues have been addressed, a location-led dedicated vaginal and pelvic pain guidance can help frame the wider differential.
Pregnancy and adolescent safeguarding
Pregnancy
Pregnancy affects antibiotic selection, follow-up and the consequences of untreated infection. Tell the clinician if you are pregnant, could be pregnant or are breastfeeding before treatment. CDC recommends a chlamydia test of cure about four weeks after treatment during pregnancy and repeat testing according to pregnancy risk and screening pathways (CDC chlamydia guidance). Gonorrhoea and trichomoniasis also require pregnancy-appropriate prescribing and follow-up.
Pregnancy with severe pain, heavy bleeding, fainting, fever, possible fluid leakage or feeling very unwell needs urgent assessment through an appropriate maternity or emergency pathway. Do not use discharge appearance or a home pH strip to distinguish infection from amniotic fluid. See vaginal discharge during pregnancy for a focused safety guide.
Adolescents and children
Adolescents deserve respectful, nonjudgmental care. Confidentiality is not absolute everywhere; consent, mandatory reporting and safeguarding rules depend on age, capacity, risk and local law. A qualified service should explain what can remain private and when safety concerns require information sharing. Ask the service to explain its confidentiality policy and any legal limits.
Possible coercion, assault, exploitation or an age-discrepant sexual situation needs a safeguarding-sensitive response. The person’s immediate safety and choices should guide communication where the law allows. Avoid demanding a detailed account outside an appropriate clinical setting.
In a prepubertal child, unexpected discharge or bleeding, foul odour, pain, a suspected foreign body, injury or possible abuse requires qualified pediatric assessment and safeguarding pathways. Do not instruct the child to insert anything, do not probe or collect an internal sample, and do not attempt foreign-body removal at home. Internal speculum examinations are not routine for children.
🚨 Red flags
Call 997 in Saudi Arabia or go to the nearest emergency department for collapse or fainting, severe or rapidly worsening pelvic or abdominal pain, heavy bleeding, confusion, breathing difficulty or severe systemic illness (Saudi national portal).
Seek prompt qualified assessment for:
- pelvic or lower-abdominal pain with fever, vomiting, abnormal bleeding or feeling very unwell;
- pregnancy with pain, bleeding, fever, possible fluid leakage or concerning symptoms;
- genital ulcers, blisters, marked swelling, severe urinary symptoms or rapidly worsening pain;
- discharge with bleeding after sex or between periods;
- symptoms after a known STI exposure, a partner’s positive result or sexual assault;
- symptoms that persist after treatment or return quickly;
- a child or adolescent with unexpected discharge, bleeding, injury, a suspected foreign body or abuse concern.
For non-emergency official health navigation in Saudi Arabia, MOH 937 may provide general advice. It does not replace emergency care or prove the availability of a particular test.
Frequently asked questions
1. Which STIs can cause vaginal discharge?
Trichomoniasis can cause vaginitis and discharge, while chlamydia and gonorrhoea can cause cervicitis with discharge or bleeding. All three may cause no symptoms, and discharge appearance cannot identify which infection is present (CDC trichomoniasis guidance; CDC cervicitis guidance).
2. Can I have chlamydia or gonorrhoea with normal discharge?
Yes. Chlamydia and gonorrhoea are often asymptomatic, so normal-looking discharge does not rule them out. Testing should follow exposure, screening criteria and clinical context rather than symptoms alone.
3. What colour is gonorrhoea or trichomoniasis discharge?
There is no diagnostic colour. Both infections can produce variable discharge or no symptoms, and similar colours occur with BV, yeast, irritation and normal changes. Use infection-specific testing, not a colour chart.
4. Does one vaginal swab test for every STI?
No. A sample tests only for the organisms and sites covered by the ordered assay. Blood tests or throat, rectal, urine, cervical or vaginal samples may be needed according to anatomy and exposure.
5. How soon after exposure should I test?
There is no universal STI window. Timing depends on the organism, assay and specimen; an early negative may need repetition. Ask the testing service for the window of the exact test, and seek immediate advice if symptoms or time-sensitive post-exposure care are relevant.
6. When do I need a test of cure or retest?
The rule varies. CDC recommends test of cure for chlamydia in pregnancy at about four weeks and for pharyngeal gonorrhoea 7 to 14 days after treatment, while retesting after chlamydia, gonorrhoea or trichomoniasis is generally advised at about three months to detect reinfection (CDC chlamydia guidance; CDC gonorrhoea guidance; CDC trichomoniasis guidance).
7. Does my partner always need treatment?
No single rule covers every infection. Recent partners generally need evaluation and presumptive treatment for confirmed chlamydia or gonorrhoea, and current partners need concurrent treatment for trichomoniasis; timing and methods follow the diagnosis and local pathway (CDC; CDC; CDC).
8. Does discharge with pelvic pain mean PID?
It may raise concern, but it does not prove PID. Because PID can be mild or nonspecific and early treatment matters, pelvic or lower-abdominal pain with fever, abnormal bleeding, vomiting, pain with sex or feeling unwell needs prompt clinical assessment (CDC PID guidance).
The bottom line
Vaginal discharge is not an STI test. Chlamydia, gonorrhoea and trichomoniasis may cause discharge, irritation, urinary symptoms or bleeding, but each can also remain silent. The safest pathway starts with exposure and anatomy, uses the right test at the right site and time, then follows infection-specific treatment, retesting and partner advice.
Do not infer infidelity from a result, take leftover antibiotics or apply one partner rule to every diagnosis. Escalate pelvic pain, fever, vomiting or severe illness because PID can be subtle. Children and adolescents need age-appropriate consent, confidentiality explanations and safeguarding-sensitive assessment, never a home internal examination.
If discharge is persistent or accompanied by bleeding, urinary symptoms, possible exposure or pelvic discomfort, consider a general gynecological assessment. Seek emergency care for severe or life-threatening features. Confirm testing, partner-care and urgent pathways directly with the service you plan to use.
References
- Centers for Disease Control and Prevention. Trichomoniasis. STI Treatment Guidelines.
- Centers for Disease Control and Prevention. Urethritis and Cervicitis. STI Treatment Guidelines.
- Centers for Disease Control and Prevention. Chlamydial Infections. STI Treatment Guidelines.
- Centers for Disease Control and Prevention. Gonococcal Infections Among Adolescents and Adults. STI Treatment Guidelines.
- Centers for Disease Control and Prevention. Pelvic Inflammatory Disease. STI Treatment Guidelines.
- World Health Organization. Trichomoniasis.
- World Health Organization. Recommendations for the treatment of Trichomonas vaginalis, Mycoplasma genitalium, Candida albicans, bacterial vaginosis and human papillomavirus, 2024.
- World Health Organization. Updated recommendations for the treatment of Neisseria gonorrhoeae and Chlamydia trachomatis, 2024.
- IUSTI Europe. European Guideline for the Management of Vaginal Discharge, 2023.
- NHS. Pelvic inflammatory disease.
- US Food and Drug Administration. Vaginal pH home-use tests.
- Saudi national portal. Emergency contacts.